AIM vs. ATRA, TIL, PASG, CVM, AVRO, ENTX, CRIS, IKNA, GNTA, and TSBX
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Atara Biotherapeutics (ATRA), Instil Bio (TIL), Passage Bio (PASG), CEL-SCI (CVM), AVROBIO (AVRO), Entera Bio (ENTX), Curis (CRIS), Ikena Oncology (IKNA), Genenta Science (GNTA), and Turnstone Biologics (TSBX). These companies are all part of the "biological products, except diagnostic" industry.
AIM ImmunoTech (NYSE:AIM) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Atara Biotherapeutics has a consensus price target of $28.00, indicating a potential upside of 4,891.98%. Given Atara Biotherapeutics' higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than AIM ImmunoTech.
Atara Biotherapeutics has a net margin of -671.70% compared to AIM ImmunoTech's net margin of -16,123.32%. AIM ImmunoTech's return on equity of -191.38% beat Atara Biotherapeutics' return on equity.
AIM ImmunoTech has higher earnings, but lower revenue than Atara Biotherapeutics. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
AIM ImmunoTech has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
In the previous week, Atara Biotherapeutics had 2 more articles in the media than AIM ImmunoTech. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 1 mentions for AIM ImmunoTech. Atara Biotherapeutics' average media sentiment score of 0.97 beat AIM ImmunoTech's score of -0.75 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.
12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Atara Biotherapeutics received 373 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 67.56% of users gave Atara Biotherapeutics an outperform vote.
Summary
Atara Biotherapeutics beats AIM ImmunoTech on 11 of the 16 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
